

PUBLIKATIONSVERZEICHNIS

Wissenschaftliche Originalarbeiten

1. **Kagan KO**, Sroka F, Sonek J, Abele H, Luthgens K, Schmid M, Wagner P, Brucker S, Wallwiener D, Hoopmann M.
First trimester screening based on ultrasound and cfDNA vs. first-trimester combined screening - a randomized controlled study.
Ultrasound Obstet Gynecol. 2017, angenommen
Impact Factor: 4,710
2. Wagner P, Sonek J, Klein J, Hoopmann M, Abele H, **Kagan KO**.
First-trimester ultrasound screening for trisomy 21 based on maternal age, fetal nuchal translucency, and different methods of ductus venosus assessment.
Prenat Diagn. 2017 Jul;37(7):680-685.
Impact Factor: 2,523
3. Wagner P, Sonek J, Hoopmann M, Abele H, **Kagan KO**.
First-trimester screening for trisomy 18, 13, triploidy and Turner syndrome by a detailed early anomaly scan.
Ultrasound Obstet Gynecol. 2016 Oct;48(4):446-451.
Impact Factor: 3,853
4. Hoopmann M, Sonek J, Esser T, Bilardo CM, Wagner P, Abele H, **Kagan KO**
The frontal space measurement in facial clefts and retrognathia at 11-13 weeks' gestation.
Ultrasound Obstet Gynecol. 2016 Aug;48(2):171-6.
Impact Factor: 3,853
5. Abele H, Wagner P, Sonek J, Hoopmann M, Brucker S, Artunc-Ulkumen B, **Kagan KO**.
First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow.
Prenat Diagn. 2015;35(12):1182-6
Impact Factor: 3,268
6. **Kagan KO**, Schmid M, Hoopmann M, Wagner P, Abele H.
Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21.
Geburtshilfe Frauenheilkd. 2015 Mar;75(3):244-250.
Impact Factor: 0,936
7. **Kagan KO**, Wright D, Nicolaidis KH.
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Ultrasound Obstet Gynecol. 2015 Jan;45(1):42-7.
Impact Factor: 3,853
8. **Kagan KO**, Hoopmann M, Hammer R, Stressig R, Kozlowski P.
Screening for chromosomal abnormalities by first trimester combined screening and noninvasive prenatal testing.
Ultraschall Med. 2015;36(1):40-6. Impact Factor: 4,924
9. **Kagan KO**, Sonek J, Berg X, Berg C, Mallmann M, Abele H, Hoopmann M, Geipel A.
Facial markers in second- and third-trimester fetuses with trisomy 18 or 13, triploidy or Turner syndrome.
Ultrasound Obstet Gynecol. 2015;46(1):60-5.
Impact Factor: 3,853
10. Yazdi B, Riefler P, Fischmuller K, Sonek J, Hoopmann M, **Kagan KO**.
The frontal space measurement in euploid and aneuploid pregnancies at 11-13 weeks' gestation.
Prenat Diagn. 2013;33:1124-30.
Impact Factor: 2,514
11. Luthgens K, Merz E, Hackeloer BJ, Thode C, Eiben B, **Kagan KO**.
Comparison of three first trimester screening algorithms for trisomy 21 with and without adjustment for maternal characteristics.

Ultraschall Med. 2013;34:151-6.

Impact Factor: 4,645

12. **Kagan KO**, Hoopmann M, Abele H, Alkier R, Luthgens K.
First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β -human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Ultrasound Obstet Gynecol. 2012;40:530-5.

Impact Factor: 3,557

13. Luthgens K, Hoopmann M, Alkier R, Abele H, Yazdi B, **Kagan KO**.
[First-trimester screening for trisomies 18 and 13 with the combined use of the risk algorithms for trisomy 21, 18 and 13].

Ultraschall Med. 2012;33:E57-61.

Impact Factor: 4,116

14. **Kagan KO**, Hoopmann M, Baker A, Huebner M, Abele H, Wright D.

Impact of bias in crown-rump length measurement at first-trimester screening for trisomy 21.

Ultrasound Obstet Gynecol. 2012;40:135-9.

Impact Factor: 3,557

15. Chaoui R, Benoit B, Heling KS, **Kagan KO**, Pietzsch V, Sarut Lopez A, Tekesin I, Karl K.
Prospective detection of open spina bifida at 11-13 weeks by assessing intracranial translucency and posterior brain.

Ultrasound Obstet Gynecol. 2011;38:722-6.

Impact Factor: 3,007

16. **Kagan KO**, Abele H, Yazdi B, Boer B, Pintoffl P, Wright D, Hoopmann M.

Intra- and inter-operator repeatability of manual and semi-automated measurement of increased fetal nuchal translucency according to the operator's experience

Prenat Diagn. 2011;31:1229-33.

Impact Factor: 2,106

17. Abele H, Luthgens K, Hoopmann, M, **Kagan KO**

Impact of the maternal age-related risk in first trimester combined screening for trisomy 21. Fetal Diagn Ther. 2011;30:135-40.

Impact Factor: 1,048

18. Luthgens K, Abele H, Alkier R, Hoopmann M, **Kagan KO**

Cross-Validierung des Screening-Algorithmus der FMF London an 38.000 Ersttrimester-Untersuchungen in Deutschland.

Ultraschall Med. 2011;32:367-72.

Impact Factor: 2,398

19. Wright D, Abele H, Baker A, **Kagan KO**

The impact of bias in serum-free β -hCG and PAPP-A MoM levels on first trimester screening for trisomy 21.

Ultrasound Obstet Gynecol. 2011;38:309-13.

Impact Factor: 3,007

20. **Kagan KO**, Staboulidou I, Cruz J, Wright D, Nicolaides KH

Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing

Ultrasound Obstet Gynecol. 2010;36:542-7.

Impact Factor: 3,163

21. Wright D, Spencer K, **Kagan K**, Topping N, Petersen OB, Christou A, Kallikas J, Nicolaides KH

First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation

Ultrasound Obstet Gynecol. 2010;36:404-11.

Impact Factor: 3,163

22. Abele H, Hoopmann M, Wright D, Hoffmann-Poell B, Huettelmaier M, Pintoffl K, Wallwiener D, **Kagan KO**

Intra- and interoperator reliability of manual and semi-automated measurement of fetal nuchal translucency by sonographers with different levels of experience

- Ultrasound Obstet Gynecol. 2010;36:417-22.
Impact Factor: 3,163
23. **Kagan KO**, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH.
The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis
Ultrasound Obstet Gynecol. 2010;36:10-4.
Impact Factor: 3,163
24. Abele H, Hoopmann M, Grischke EM, Wallwiener D, **Kagan KO**
Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency
Ultrasound Obstet Gynecol. 2010;35:525-9.
Impact Factor: 3,163
25. **Kagan KO**, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
Prospective validation of first-trimester combined screening for trisomy 21
Ultrasound Obstet Gynecol. 2009;34:14-8.
Impact Factor: 3,154
26. **Kagan KO**, Wright D, Etchegaray A, Zhou Y, Nicolaides KH
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy
Ultrasound Obstet Gynecol. 2009;33:657-64.
Impact Factor: 3,154
27. Maiz N, Valencia C, **Kagan KO**, Wright D, Nicolaides KH
Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation
Ultrasound Obstet Gynecol. 2009;33:512-7.
Impact Factor: 3,154
28. **Kagan KO**, Cicero S, Staboulidou I, Wright D, Nicolaides KH
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Ultrasound Obstet Gynecol. 2009;33:259-64.
Impact Factor: 3,154
29. **Kagan KO**, Valencia C, Livanos P, Wright D, Nicolaides KH
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0-13+6 weeks of gestation
Ultrasound Obstet Gynecol. 2009;33:18-22.
Impact Factor: 3,154
30. **Kagan KO**, Anderson JM, Anwandter G, Neksasova K, Nicolaides KH
Screening for triploidy by the risk algorithms for trisomy 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation
Prenat Diagn. 2008;28:1209-13.
Impact Factor: 1,596
31. **Kagan KO**, Wright D, Maiz N, Pandeva I, Nicolaides KH
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β -human chorionic gonadotropin and pregnancy-associated plasma protein-A
Ultrasound Obstet Gynecol. 2008;32:488-92.
Impact Factor: 2,690
32. **Kagan KO**, Wright D, Valencia C, Maiz N, Nicolaides KH
Screening for trisomy 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β -hCG and pregnancy-associated plasma protein-A
Human reproduction 2008;19:1968-75.
Impact Factor: 3,773
33. **Kagan KO**, Wright D, Baker A, Sahota D, Nicolaides KH
Screening for trisomy 21 by maternal age fetal nuchal translucency thickness, free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A
Ultrasound Obstet Gynecol 2008;31:618-24.
Impact Factor: 2,690
34. Borenstein M, Persico N, **Kagan KO**, Gazzoni, A, Nicolaides KH

- Frontomaxillary facial angle in screening for trisomy 21 at 11+0 to 13+6 weeks
Ultrasound Obstet Gynecol 2008;32:5-11.
Impact Factor: 2,690
35. **Kagan KO**, Wright D, Spencer K, Molina FS, Nicolaides KH
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics
Ultrasound Obstet Gynecol 2008;31:493-502.
Impact Factor: 2,690
36. Wright D, **Kagan KO**, Molina FS, Gazzoni A, Nicolaides KH
A mixture model of nuchal translucency thickness in screening for chromosomal defects
Ultrasound Obstet Gynecol. 2008;31:376-83.
Impact Factor: 2,690
37. Spencer K, Cowans NJ, Molina F, **Kagan KO**, Nicolaides KH
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery
Ultrasound Obstet Gynecol. 2008;31:147-52.
Impact Factor: 2,690
38. Spencer K, **Kagan KO**, Nicolaides KH
Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
Prenat Diagn. 2008;28:49-52.
Impact Factor: 1,596
39. **Kagan KO**, Frisova V, Nicolaides KH, Spencer K
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation
Prenat Diagn. 2007;27:849-53.
Impact Factor: 1,514
40. Cicero S, Avgidou K, Rembouskos G, **Kagan KO**, Nicolaides, KH
Nasal bone in first-trimester screening for trisomy 21
Am J Obstet Gynecol. 2006;195:109-14.
Impact Factor: 2,805
41. Molina FS, Avgidou K, **Kagan KO**, Poggi S, Nicolaides KH
Cystic hygromas, nuchal edema, and nuchal translucency at 11-14 weeks of gestation
Obstet Gynecol. 2006;107:678-83.
Impact Factor: 3,813
42. Chitty LS, **Kagan KO**, Molina FS, Waters JJ, Nicolaides KH
Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study
BMJ. 2006;332:452-5.
Impact Factor: 9,245
43. **Kagan KO**, Avgidou K, Molina FS, Gajewska K, Nicolaides KH
Relation between increased fetal nuchal translucency thickness and chromosomal defects
Obstet Gynecol 2006;107:6–10.
Impact Factor: 3,813

Übersichtsarbeiten

1. Hoopmann M, **Kagan KO**.

Das fetale Profil – mehr als nur NT
Ultraschall Med. 2017, angenommen
Impact Factor: 3,892

2. **Kagan KO**, Sonek J, Wagner P, Hoopmann M.

Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.

Arch Gynecol Obstet. 2017, angenommen

Impact Factor: 2,090

3. **Kagan KO**, Sonek J, Wagner P, Hoopmann M.

Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for other major defects and pregnancy complications.

Arch Gynecol Obstet. 2017, angenommen

Impact Factor: 2,090

4. Salomon LJ, Alfirevic Z, Audibert F, **Kagan KO**, Paladini D, Yeo G, Raine-Fenning N; ISUOG Clinical Standards Committee.

ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice.

Ultrasound Obstet Gynecol. 2017 Jun;49(6):815-816.

Impact Factor: 4,710

5. Grati FR, **Kagan KO**.

Rate of no result in cell-free DNA testing and its influence on test performance metrics.

Ultrasound Obstet Gynecol. 2017 Jul;50(1):134-137.

Impact Factor: 4,710

6. Rempen A, Chaoui R, Hausler M, **Kagan KO**, Kozlowski P, von Kaisenberg C, Wisser J
Quality Requirements for Ultrasound Examination in Early Pregnancy (DEGUM Level I) between 4+0 and 13+6 Weeks of Gestation.

Ultraschall Med. 2016 Dec;37(6):579-583.

Impact Factor: 4,924

7. von Kaisenberg C, Chaoui R, Hausler M, **Kagan KO**, Kozlowski P, Merz E, Rempen A, Steiner H, Tercanli S, Wisser J, Heling KS.

Quality Requirements for the early Fetal Ultrasound Assessment at 11-13+6 Weeks of Gestation (DEGUM Levels II and III).

Ultraschall Med. 2016 Jun;37(3):297-302.

Impact Factor: 4,924

8. Sonek JD, **Kagan KO**, Nicolaides KH.

Inverted Pyramid of Care.

Clin Lab Med. 2016;36(2):305-17.

Impact Factor: 1,366

9. Yagel S, Cohen SM, Benacerraf BR, Cuckle H, **Kagan KO**, Van den Veyver I, Wapner R, Lee W.

Noninvasive prenatal testing and fetal sonographic screening: roundtable discussion.

J Ultrasound Med. 2015;34(3):363-9. Impact Factor: 1,535

10. Salomon LJ, Alfirevic Z, Audibert F, **Kagan KO**, Paladini D, Yeo G, Raine-Fenning N; ISUOG Clinical Standards Committee.

ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice.

Z Geburtshilfe Neonatol. 2014 Dec;218(6):242-3.

Impact Factor: 0,483

11. Eiben B, Glaubitz R, **Kagan KO**

Nichtinvasive Pränataldiagnostik ETS und NGS-basierte Tests

Medizinische Genetik medgen 2014, 26:382-90

Impact Factor: 0,130

12. Salomon LJ, Alfirevic Z, Audibert F, **Kagan KO**, Paladini D, Yeo G, Raine-Fenning N; ISUOG Clinical Standards Committee.

ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice.

Ultrasound Obstet Gynecol. 2014;44(1):122-3..

Impact Factor: 3,853

13. **Kagan KO**, Eiben B, Kozlowski P.

Kombiniertes Ersttrimesterscreening und zell-freie fetale DNA – „Next generation screening“

Ultraschall Med. 2014 Jun;35(3):229-36

Impact Factor: 4,924

14. **Kagan, KO**, Hoopmann, M und Kozlowski, P.

Assessment of Foetal DNA in Maternal Blood – A Useful Tool in the Hands of Prenatal Specialists.

Geburtsh Frauenheilk, 2013;72(11), 998–1003.

Impact Factor: 0,962